Table 2.
Characteristics of the included studies on the incidence of endometrial cancer in BRCAm patients.
| Authors | Publication Year | Country | Time Period | Study Type | Study Group |
|---|---|---|---|---|---|
| Thompson et al. [29] | 2002 | Western Europe and North America | 1960–2002 | Retrospective multicenter cohort | BRCAm |
| Beiner et al. [30] | 2007 | North America, Europe and Israel | NA | Prospective multicenter cohort | BRCAm |
| Reitsma et al. [14] | 2012 | The Netherlands | 1996–2012 | Prospective cohort | BRCAm, RRSO |
| Segev et al. [31] | 2013 | Canada, Italy, USA, Austria, Poland, Norway | NA | Prospective multicenter case-control | BRCAm |
| Casey et al. [13] | 2015 | USA | 1959–2013 | Retrospective cohort | BRCAm with invasive gynecologic and/or peritoneal cancers |
| Segev et al. [32] | 2015 | North America, Europe and Israel | NA | Retrospective multicenter case-control | BRCAm |
| Shu et al. [12] | 2016 | USA, UK | 1995–2011 | Prospective multicenter cohort | BRCAm, RRSO |
| Zakhour et al. [33] | 2016 | USA | 2000–2014 | Prospective cohort | BRCAm, RRSO |
| Bogani et al. [34] | 2017 | Italy | 2014–2017 | Prospective cohort | BRCAm or significant family history of breast/ovarian cancer, RRSO ± hysterectomy |
| Lee et al. [35] | 2017 | Australia, New Zealand |
NA | Prospective multicenter cohort | BRCAm |
| Minig et al. [36] | 2018 | Spain | 2010–2017 | Retrospective multicenter cohort |
BRCAm, RRSO |
| Saule et al. [15] | 2018 | France | 1996–2016 | Prospective cohort | BRCAm, RRSO |
| Laitman et al. [11] | 2019 | Israel | 1998–2016 | Retrospective case-control | BRCAm |
| Kitson et al. [37] | 2020 | UK | 1991–2017 | Retrospective cohort | BRCAm |
BRCAm: breast cancer gene 1/2 mutation, RRSO: risk-reducing salpingo-oophorectomy, NA: not available.